Page 1283 - Small Animal Internal Medicine, 6th Edition

CHAPTER 73 Common Immune-Mediated Diseases 1255

Wang A, et al. Treatment of canine idiopathic immune-mediated Weiss DJ. Evaluation of antineutrophil IgG antibodies in persis-
tently neutropenic dogs. J Vet Intern Med. 2007;21:440.
haemolytic anaemia with mycophenolate mofetil and glucocor- Whelan M, et al. Use of human immunoglobulin in addition to
VetBooks.ir Webb AA, et al. Steroid responsive meningitis-arteritis in dogs with glucocorticoids for the initial treatment of dogs with immune
ticoids: 30 cases (2007-2011). J Small Anim Pract. 2013;54(8):399.
noninfectious nonerosive idiopathic immune-mediated polyar-
mediated hemolytic anemia. J Vet Emerg Crit Care. 2009;19:158.
thritis. J Vet Intern Med. 2002;16:269. Wondratschek C, et al. Primary immune-mediated thrombocyto-
Weinkle TK, et al. Evaluation of prognostic factors, survival rates, penia in cats. J Am Anim Hosp Assoc. 2010;46:12.
and treatment protocols for immune-mediated hemolytic anemia Wu X, et al. Autoantibodies in canine masticatory muscle myositis
in dogs: 151 cases (1993-2002). J Am Vet Med Assoc. 2005;226:1869. recognize a novel myosin binding protein C family member. J
Weiss DJ. Primary pure red cell aplasia in dogs: 13 cases (1996-2000). Immunol. 2007;179:4939.
J Am Vet Med Assoc. 2002;221:93.

Drugs Used to Treat Immune-Mediated Diseases of Dogs and Cats and General Dosing Guidelines

GENERIC NAME RECOMMENDED DOSE
(TRADE NAME) PURPOSE DOG CAT

Aspirin Prevent thromboembolic 0.5 mg/kg PO q24h NA
complications of
IMHA or PLN
Azathioprine (Imuran) Immunosuppression 2 mg/kg/day initially. Dose can Not recommended
be decreased to every other
day to reduce risk of toxicity
Chlorambucil (Leukeran) Immunosuppression 0.1-0.2 mg/kg PO q24h initially, 0.1-0.2 mg/kg PO q24h initially,
then taper to every other day then q24-72h
once a response is seen
Clopidogrel (Plavix) Prevent thromboembolic 1-2 mg/kg PO q24h 1-2 mg/kg PO q24h, or
complications of 18.75 mg/cat PO q24h
IMHA or PLN
Cyclosporine (Atopica, Immunosuppression 5-10 mg/kg PO q12-24h 3-5 mg/kg PO q12h
Neoral) Recommend using only Atopica® Recommend using only Atopica®
due to concerns for due to concerns for
bioavailability of other products bioavailability of other products
Lower doses of 1-2.5 mg/kg q12h
if in conjunction with
ketoconazole
Dexamethasone Immunosuppression 0.25-0.5 mg/kg PO q24h 0.25-1 mg/kg PO q24h
Enalapril (Enacard) Treatment of proteinuria 0.5-1.0 mg/kg q12-24h NA
Famotidine (Pepcid) Treatment and 0.5-mg/kg PO/IM/SC q12-24h 0.5 mg/kg PO/IM/SC q12-24h
prevention of gastric
ulceration
Heparin (unfractionated) Anticoagulation 200-300 U q6h as initial dose. NA
Adjust on basis of measurement
of aPTT or anti-Xa activity
hIVIG Immunosuppression 0.25-1.5 g/kg as an IV infusion NA
over 6-12 hours (one dose only)
Leflunomide (Arava) Immunosuppression 2-4 mg/kg PO q24h NA
Mycophenolate mofetil Immunosuppression 10 mg/kg q12h 10 mg/kg q12h
(CellCept)
Neostigmine Anticholinesterase 0.04 mg/kg IM q6h 0.04 mg/kg IM q6h
(Prostigmin) inhibitor
Continued